PT  - JOURNAL ARTICLE
AU  - Mosley, Mary
ED  - Brightling, Christopher E.
TI  - Tralokinumab Reduced Acute Exacerbations in a Phase 2 Study of Severe Asthma
DP  - 2014 Sep 01
TA  - MD Conference Express
PG  - 11--11
VI  - 14
IP  - 11
4099  - http://mdc.sagepub.com/content/14/11/11.1.short
4100  - http://mdc.sagepub.com/content/14/11/11.1.full
AB  - Tralokinumab, a human immunoglobulin-G4 monoclonal antibody, potently and specifically neutralizes interleukin (IL)-13, a pleiotropic cytokine thought to be a central mediator of asthma [Mitchell J et al. Curr Opin Investig Drugs 2010]. This article presents the overall results from A Phase 2b, Randomized, Double-Blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma [NCT01402986; Brightling CE et al. Am J Crit Care Med 2014].